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ABSTRACT  
Epidemic keratoconjunctivitis (EKC), caused by certain species D human adenoviruses (Ads), is a highly 
contagious severe disease involving both the conjunctiva and cornea. The hallmark of this disease is the 
subepithelial infiltration of leukocytes, which results in corneal opacities that may persist for months or 
even years. 
In this case, of a 6-month-old infant, we report a symblepharon formation, a relatively rare outcome of 
EKC. In this condition, the palpebral conjunctiva adheres tightly to the bulbar conjunctiva of the eyeball. 
Our report is the first documentation of a symblepharon formation in an infant. Only two similar cases have 
been reported to date; therefore, a detailed description is of considerable interest to ophthalmologists. 
This is particularly interesting since a previous publication has associated symblepharon formation with an 
adenovirus infection, which is not usually involved in EKC. The development of a symblepharon following 
EKC is rare in infants. Since topical treatment cannot be applied due to severe eyelid edema, oral steroid 
therapy can be administered with pediatric consultation and meticulous monitoring. 
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INTRODUCTION 
Epidemic keratoconjunctivitis (EKC) is considered a 
distressing contagious infection of the ocular surface (1). 
Adenoviral conjunctivitis is epidemic in adult and 
pediatric populations (2). The transmission of adenovirus 
occurs primarily through hand-to-eye contact, 
respiratory droplets, eye secretions, and contact with 
healthcare providers and their medical equipment. The 
most frequent manifestation of an ocular adenoviral 
infection is epidemic keratoconjunctivitis, followed by 
pharyngoconjunctival fever. Epidemic 
keratoconjunctivitis is the most rigorous form of disease 
caused by adenovirus and presents with watery 
discharge, chemosis, hyperemia, and unilateral 
lymphadenopathy (2). 
Moreover, the incubation period fluctuates from 4 hours 
to 3 weeks and the symptoms may last for 7-21 days. As 
a biphasic disease, adenoviral conjunctivitis starts with 
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an infective period followed by an inflammatory phase. 
The inflammatory period commences around a week 
followed by the initial infection as the virus continues to 
shed (3). It is usually diagnosed on the basis of symptoms 
and clinical manifestations. Although Laboratory 
evaluation is mostly not necessary, it can be beneficial 
for the diagnosis (4). 
Keratoconjunctivitis may be severe, sometimes causing 
substantial morbidity. The distinguishing characteristic of 
EKC is involvement of the whole ocular surface area, 
along with the surface of the conjunctival and corneal 
epithelium. In severe cases, pseudomembranes and 
symblepharon may form and multifocal subepithelial 
infiltrates may reduce visual acuity for a long duration 
(1). The configuration of pseudomembranes includes 
sheets of fibrin exudates lacking blood vessels. It is a 
frequent complication in EKC, particularly in infections 
associated with specific serotypes, such as 8, 19, and 37 
(2). This suggests that true conjunctival membranes can 
and do form in EKC. When removed, these true 
membranes can cause bleeding, while their persistence 
may cause subepithelial fibrosis and the formation of a 
symblepharon. 
Several topical treatment methods have been used for 
EKC. The majority of them are prophylactic, including 
preservative-free antibiotics and artificial tears. Some 
authors have found that 2.5% povidone iodine is an 
effective treatment for EKC (5). Viral protein remnants 
frequently persist on the corneal surface of Bowman’s 
layer for a long period and may form subepithelial 
infiltrates, which are challenging to treat. Cyclosporin A 
eye drops are a respectable option for the low risk cases. 
The use of topical steroids has potential 
disadvantageous; however, using them may be 
considered at any stage of the disease (3). 
 
CASE REPORT 
We obtained signed statement from the patient's 
parents and our hospital ethical committee, which 
authorized the use of the patient's personal and/or 
medical information for the publication of our study. 
Multiple cases of EKC had been reported in our hospital. 
The polymerase chain reaction findings for one patient 
showed that the EKC was caused by adenovirus serotype 
19. A 6-month-old infant presented with EKC in both 
eyes. His 1- and 3-month postpartum eye exams had 
normal findings. The patient’s mother had EKC 20 days 
prior and was treated with topical drops at our clinic. The 
infection in the son began one day prior to the hospital 
visit. The patient underwent inspection and direct 
ophthalmoscopy, which showed bilateral epiphora, 
chemosis, severe eyelid edema, and preauricular 
lymphadenopathy. The eyelid was forced open and there 
was no corneal staining with fluorescein. Topical 
preservative-free antibiotics, artificial tears, and 
loteprednol etabonate drops were prescribed. In 
addition, conjunctival irrigation was performed with 2.5% 
povidone iodine. The patient failed to return for a 3-day 
follow-up visit, but returned 21 days after the 
examination, when the mother said that the treatment 
could not be administered because of the edema and 
pain. Examination showed improvement of the eyelid 
edema and normal corneas; however, there were 
bilateral conjunctival scars and a symblepharon 
formation in the lower left eyelid between the temporal 
palpebral conjunctiva and bulbar conjunctiva. Eye 
movements were not restricted. The patient was treated 
with weak steroids and artificial tear drops, but the 
symblepharon persisted for at least three years (Figure 
1). 
 
Figure 1. Persistent symblepharon after 3 years following 
treatment. 
 
DISCUSSION 
The main concern in the treatment of cases with definite 
or suspected EKC is meticulous hygiene practices mainly 
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because there is still no efficient medication for this 
disease. No virostatic agent has been shown to affect the 
course of the virus (4). In mild cases, a prescription for 
artificial tears, cold compresses, and vasoconstrictors 
may be effective. In more severe cases, topical steroids 
should be prescribed when the disease causes the 
formation of a pseudomembrane. Based on the severity 
of the case, an ophthalmologist may remove 
pseudomembranes on an individual basis (3). 
Hammer et al. (6) presented two case reports in which 
patients with EKC developed symblepharon during the 
course of infection. That was the first report of 
symblepharon formations associated with adenovirus 
type 2. The first case involved an 82-year-old woman 
who had previously undergone a keratoplasty operation. 
In that case, the symblepharon formation was 
completely reversed after continued lysis with a glass 
rod. The second case involved a healthy 47-year-old 
woman with no previous ocular disease. The 
symblepharon formation remained unchanged during the 
18 months of observation. Initial treatment for both 
patients was topical antibiotics and steroids (6). Our 
report is the first of a symblepharon formation in an 
infant. We treated the patient with topical preservative-
free antibiotics, artificial tears, loteprednol etabonate for 
severe eyelid edema, and irrigation of the conjunctiva 
with 2.5% povidone iodine.  
Topical steroids are crucial when a pseudomembrane 
forms. Eye drops with 0.12% prednisolone acetate, 0.1% 
fluorometholone, 1% rimexolone, dexamethasone, and 
0.001% loteprednol etabonate may be applied, and eye 
drops with 1.0% prednisolone or 0.5% loteprednol 
etabonate are recommended while keratitis is present 
(7). Nonsteroidal anti-inflammatory drugs (NSAIDs) or 
oral steroids may be prescribed for symptomatic relief in 
younger patients less than 3 years of age with severe EKC 
and inflammatory ptosis (7). It should be noted that in 
our case, we treated conservatively and did not use an 
oral steroid or any nonsteroidal medications. 
Studies showed that virostatic agents such as trifluridine, 
vidarabine, and ganciclovir may be effective against 
adenovirus; however, the latest studies regarding their 
efficacy for the treatment of adenoviral conjunctivitis are 
still notorious (2). Povidone-iodine as a broad-spectrum 
antiseptic may be effective against free adenovirus, but 
research has shown that it is less efficient against 
intracellular adenovirus (5). 
Irrigation of conjunctiva with 2.5% povidone iodine is an 
effective treatment for adenoviral conjunctivitis in 
infants (5). Tunay et al. report significantly lower clinical 
scores and reduced recovery time in infants irrigated 
with a 2.5% povidone iodine solution when compared to 
those without conjunctival irrigation. We recommend 
calling the parents of infant patients every three days to 
receive an update on symptoms; this can enable repeat 
irrigation if required. Unfortunately, our patient did not 
return for a 3-day check-up; thus, we were unable to 
repeat irrigation. 
Short-term oral steroid therapy rapidly improves eyelid 
edema, inflammatory ptosis, and corneal erosion. Kim et 
al. (7) recommend prescribing oral steroids, especially 
when there is poor application of eye drops in patients 
with EKC who are younger than 3 years of age. Based on 
the severity of the symptoms, they initially administered 
a 0.6 mg/kg dose of oral prednisolone, which was 
increased up to 1.0 mg/kg at the pediatrician’s discretion. 
Short-term oral steroids were discontinued without 
tapering as soon as the symptoms improved. 
Pseudomembranes were removed as soon as possible; 
however, removal was difficult in non-compliant patients 
due to eyelid swelling and ocular pain. Pseudomembrane 
removal was promising 2 to 3 days following initiation of 
oral steroid therapy. However, oral steroids have some 
side effects such as the reduction of the growth rate by 
decreasing the function of the hypothalamus–pituitary–
adrenal axis, reduction in bone density, and the 
development of Cushing syndrome, hypertension, or 
diabetes (7). 
We did not administer oral steroids in our case due to 
the danger of the side effects in a 6-month-old infant. 
However, based on the symblepharon formation, we 
believe that oral steroids would have been a suitable 
treatment given that there would be a pediatric 
consultation and very strict follow-up. Steroids would 
have been particularly useful since we were unable to 
effectively administer topical treatment due to severe 
eyelid edema. However, short-term follow-up 
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examinations and pediatric consultations are required 
when administering oral steroids. 
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